NCT01311635View on ClinicalTrials.gov

A Bioavailability Study Comparing 3 Different AZD1981 Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

June 30, 2011

Conditions
Healthy
Interventions
DRUG

AZD1981, current small-particle tablet

3x100 mg per oral, single dose in fasted state

DRUG

AZD1981, new small-particle tablet

3x100 mg per oral, single dose

DRUG

AZD1981, new large-particle table

3x100 mg per oral, single dose in fasted state

Trial Locations (1)

Unknown

Research Site, Uppsala

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY